[Ofatumumab for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment – health economic evaluation]
Record ID 32018001241
Original Title: Ofatumumab til behandling av relapserende remitterende multippel sklerose: forenklet metodevurdering – helseøkonomisk evaluering
Authors' objectives: The Norwegian Institute of Public Health (NIPH) have conducted a rapid health technology assessment (HTA) of ofatumumab to treat of adults with relapsing remitting multiple sclerosis (RRMS) on behalf of the Commissioning Forum. The evaluation was performed based on the decision model in the full HTA, previously published of NIPH, of disease modifying treatments for RRMS. The model was further updated based on the data for ofatumumab.
Authors' results and conclusions: Ofatumumab is a fully human anti-CD20 monoclonal antibody and is administered as a subcutaneous injection. The results of our analyses showed that: Rituximab is the most cost-effective treatment among anti-CD20 drugs, based on current tender prices. Ocrelizumab (maximum price) is both more expensive and more effective than rituximab and cladribine (current tender prices). Ocrelizumab costs NOK xxxxxxxx per quality-adjusted life year (QALY) gained compared with rituximab and cladribine with a packing dose of NOK xxxxxxxx (xxxx reduction in drug costs) and NOK xxxxxxxx (xxxx reduction in drug costs), respectively. Ofatumumab is not yet markedet in Norway. Given the same health benefit and average annual drug cost (maximum price) as ocrelizumab, ofatumumab is both more expensive and more effective compared with rituximab and cladribine. Given the same health benefit and annual drug cost (maximum price) as ocrelizumab, ofatumumab costs NOK xxxxxxxx per QALY compared with rituximab and cladribine with a price reduction of xxxx and xxxx, respectively. A price offer of NOK xxxxxxxx (incl. VAT) per 20 mg ofatumumab gives an additional cost of NOK xxxxxxxx per QALY compared with rituximab. A price offer of NOK xxxxxxxx (incl. VAT) per 20 mg ofatumumab provides more health benefits and is less expensive than cladribine. Relapsing-remitting multiple sclerosis is a very severe disease that can cause serious disability and a loss of healthy life-years. Due to confidentiality clauses, numbers are hidden (xxxxx).
Project Status: Completed
Year Published: 2021
URL for published report: https://www.fhi.no/en/publ/2021/Ofatumumab_treatment_RRMS/
English language abstract: An English language summary is available
Publication Type: Other
- Multiple Sclerosis, Relapsing-Remitting
- Antibodies, Monoclonal, Humanized
- Cost-Benefit Analysis
Organisation Name: Norwegian Institute of Public Health
Contact Address: P.O. Box 222 Skoyen, N-0123, Oslo
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.